Keenova Therapeutics plc·4

Feb 26, 9:05 PM ET

Tyndall Mark Anthony 4

Research Summary

AI-generated summary

Updated

Keenova EVP & CLO Mark Tyndall Receives 51,794 RSUs

What Happened
Mark Tyndall (EVP, Chief Legal Officer & Corporate Secretary) received a grant of 51,794 restricted stock units (RSUs) on Feb 25, 2026. The RSUs were granted at $0.00 per unit (award/derivative), meaning no cash was paid; each RSU will convert into one ordinary share upon vesting.

Key Details

  • Transaction date: 2026-02-25; Form 4 filed 2026-02-26 (appears timely).
  • Security and amount: 51,794 RSUs (derivative award) granted at $0.00.
  • Vesting: RSUs will settle one-for-one into ordinary shares (F1). They vest ratably on each of the first three anniversaries of February 25, 2027 (F2).
  • Shares owned after transaction: not disclosed in this filing.
  • Filing note: This Form 4 also serves as notice to the issuer under Part V of the Companies Act 2014.

Context
RSU grants are a common form of executive compensation and are not purchases or sales of market shares; they typically incentivize retention and align executives with shareholder interests. Because these RSUs vest over time, they do not represent immediately tradeable shares at grant.